Nearly Half of COPD Patients Are Not Using Their Inhalers Correctly
More than 30 million Americans have chronic obstructive pulmonary disease. It is the fourth leading cause of death worldwide. Effective inhaled medications exist that reduce symptoms and cut the rate of dangerous exacerbations. And yet, depending on the study, somewhere between 43 and 58 percent of patients do not take those medications as their physician prescribed.
Two new studies published in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation dig into why - and what the consequences look like.
Cost Cuts Even the Insured
The first study drew on data from 2,521 participants in the COPD Genetic Epidemiology (COPDGene) study, who completed surveys on social and economic factors alongside their medical assessments. Cost-related nonadherence turned up in 16.2 percent of participants - 408 people who had either not filled a prescription or taken less medication than prescribed specifically because of expense or coverage gaps.
The number that stands out: 93.5 percent of those who reported cost-related nonadherence had some form of health insurance. Being insured did not protect patients from being priced out of their medication. COPD treatments are dominated by brand-name inhalers with high out-of-pocket costs, and insurance coverage frequently does not eliminate that burden.
The health consequences were measurable. Participants who skipped or reduced medications because of cost showed faster decline in lung function, more frequent exacerbations, and a higher overall symptom burden compared to those who adhered to their regimens. Those are not abstract outcomes. Exacerbations - periods of acute symptom worsening - often require hospitalization, carry their own mortality risk, and accelerate the underlying disease trajectory.
"Broader policy changes are needed to make these medications more affordable," said Rajat Suri, M.D., of the Division of Pulmonary, Critical Care, and Sleep Medicine at UC San Diego, the study's lead author. He noted specifically that two respiratory inhalers currently subject to negotiation under the Inflation Reduction Act could reduce cost-related barriers if the negotiations succeed.
Forgetfulness, Stigma, and Technique
The second study took a different approach. Researchers at a single academic medical center in Chicago conducted in-depth interviews with 17 COPD patients - a small cohort that trades statistical power for qualitative depth. Nearly half reported not taking medications as prescribed or using inhalers incorrectly.
The barriers they described were diverse. Forgetfulness was common. Physical limitations made inhaler technique difficult for some patients - a problem that matters because incorrect technique substantially reduces the amount of medication that actually reaches the lungs. Limited understanding of how or when to use different inhaler types, difficulty accessing care, stigma associated with COPD (a condition still publicly associated with smoking in ways that generate shame), and cost all appeared in the interviews.
"Medication nonadherence is common, but the reasons behind it are highly individual," said Stephanie LaBedz, M.D., of the Division of Pulmonary, Critical Care, Sleep, and Allergy at the University of Illinois Chicago, who led this study. "Physicians need to understand the full range of barriers their patients face so they can provide better education and connect them with support to ensure medications are used correctly."
The Gap Between Prescription and Practice
Taken together, the two studies sketch a picture of a treatment gap that has both structural and individual dimensions. On the structural side, drug pricing policies and insurance design create real barriers for patients who theoretically have access to treatment. On the individual side, the reasons patients do not adhere to treatment vary enough from person to person that generic patient education is unlikely to address them effectively.
Neither study offers a simple solution, and neither was designed to. But they do clarify what the problem actually consists of. For clinicians, the implication is that asking patients whether they are taking their medications is not enough - the conversation needs to cover how they are using inhalers, what they understand about their purpose, and whether cost is a factor, even if the patient has insurance. For policymakers, the cost data points toward drug pricing as a direct driver of health outcomes in a common, serious disease.
COPD is a condition that worsens over time. The medications available today cannot reverse it, but they can substantially slow its progression and reduce the crises that punctuate its course. A treatment that is prescribed but not taken is, for practical purposes, no treatment at all.